Sells exon-skipping medicines for people with Duchenne muscular dystrophy and develops gene and RNA medicines for other rare diseases.
10-K for FY2025, filed Mar 2, 2026We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique…View ↗
To date, we have developed and commercialized the following four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen)…View ↗
EXONDYS 51. We launched our first commercial product, EXONDYS 51, in 2016. EXONDYS 51 is indicated for the treatment of Duchenne in…View ↗
Customers pay for drug products delivered to their designated location, either through distribution customers who resell them or in direct sales to sites of care.
10-K for FY2025, filed Mar 2, 2026
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service (Products, net) ↗$2.2B
10-K for FY2025, filed Mar 2, 2026
$2.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
PMO Products
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
52%
FY2022: 100%
|
PMO Products, FY2025
$965.6M Sources
|
Sold outright |
|
ELEVIDYS
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
48%
FY2022: 0.0%
|
ELEVIDYS, FY2025
$898.7M Sources
|
Sold outright |
In the U.S., PMO medicines are distributed through home-infusion specialty pharmacies and a specialty distributor serving hospitals and outpatient clinics. ELEVIDYS reaches hospitals for infusion through logistics and specialty-pharmacy partners; outside the U.S., third-party distributors distribute products in certain countries through expanded-access programs.
10-K for FY2025, filed Mar 2, 2026
No. It lost $713.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$28.5MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Narrowed FY 2026 Guidance: With six months remaining for the year and consistent with prior expectations toward the lower end of the…View ↗
8-K, filed Jul 27, 2026
On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as…View ↗
Growing. Revenue grew 3.1x in 4 years, from $701.9M in FY2021 to $2.2B in FY2025, about 33% a year.
Partnered siRNA research
The latest report adds Arrowhead-partnered siRNA programs to its RNA-targeted and gene-therapy work, with candidates aimed at neuromuscular diseases and other conditions.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 2, 2026We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique…View ↗
Our siRNA programs make use of Arrowhead’s targeted RNAi molecule platform and are designed to deliver siRNA to multiple tissue and cell…View ↗
Gene therapy reaches commercial sales
The older report describes a Duchenne gene-therapy candidate in clinical development; the latest lists a gene therapy among its commercialized Duchenne products.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 2, 2026As part of our multifaceted approach to Duchenne, we are also developing gene therapy technologies to treat Duchenne. We are clinically…View ↗
Competes with Nippon Shinyaku, Italfarmaco, Wave Life Sciences, Dyne Therapeutics, Avidity Biosciences, Entrada Therapeutics, Regenxbio, BioMarin Pharmaceutical, Solid Biosciences, Genethon, Insmed, Capricor Therapeutics, Novartis, Arthex Biotech, PepGen, Vertex, Biohaven Pharmaceuticals, Celularity, uniQure, and PTC Therapeutics
10-K for FY2025, filed Mar 2, 2026EXONDYS 51, VYONDYS 53 and AMONDYS 45 were the first three disease modifying therapeutics approved by the FDA for the treatment of Duchenne…View ↗
Loading...